ESSA Historical Balance Sheet
EPIX Stock | USD 1.79 0.02 1.10% |
Trend analysis of ESSA Pharma balance sheet accounts such as Total Current Liabilities of 3 M or Total Stockholder Equity of 175.8 M provides information on ESSA Pharma's total assets, liabilities, and equity, which is the actual value of ESSA Pharma to its prevalent stockholders. By breaking down trends over time using ESSA Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining ESSA Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ESSA Pharma is a good buy for the upcoming year.
ESSA Pharma Inventory |
|
ESSA |
About ESSA Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of ESSA Pharma at a specified time, usually calculated after every quarter, six months, or one year. ESSA Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ESSA Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ESSA currently owns. An asset can also be divided into two categories, current and non-current.
ESSA Pharma Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on ESSA Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ESSA Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents ESSA Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ESSA Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of ESSA Pharma balance sheet. This account contains ESSA Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by ESSA Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most accounts from ESSA Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.At this time, ESSA Pharma's Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 139.3 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 1.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 36.4M | 1.4M | 1.6M | 1.5M | Total Assets | 169.5M | 149.1M | 171.5M | 180.1M |
ESSA Pharma balance sheet Correlations
Click cells to compare fundamentals
ESSA Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ESSA Pharma balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
Other Current Liab | 24.2M | 39.2M | 36.4M | 1.4M | 1.6M | 1.5M | |
Total Current Liabilities | 1.2M | 3.9M | 2.3M | 3.5M | 4.0M | 3.0M | |
Total Stockholder Equity | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 175.8M | |
Net Debt | (56.3M) | (137.5M) | (56.9M) | (33.6M) | (30.3M) | (31.8M) | |
Retained Earnings | (81.0M) | (117.8M) | (152.9M) | (179.5M) | (161.5M) | (153.4M) | |
Accounts Payable | 678.6K | 1.4M | 954.6K | 2.0M | 2.3M | 1.4M | |
Cash | 56.3M | 137.8M | 57.1M | 33.7M | 38.8M | 34.1M | |
Non Current Assets Total | 55.2K | 567.7K | 446.0K | 325.3K | 374.0K | 383.8K | |
Non Currrent Assets Other | (200.7K) | 277.6K | 259.5K | 257.2K | 295.8K | 181.3K | |
Cash And Short Term Investments | 56.3M | 194.9M | 57.1M | 148.1M | 170.3M | 178.8M | |
Other Current Assets | 1.7M | 2.2M | 1.8M | 585.4K | 673.2K | 1.2M | |
Other Stockholder Equity | 31.2M | 36.4M | 44.0M | 49.0M | 56.4M | 59.2M | |
Total Liab | 1.3M | 4.2M | 2.4M | 3.5M | 4.0M | 4.6M | |
Total Current Assets | 80.6M | 197.6M | 169.5M | 148.8M | 171.1M | 179.7M | |
Common Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 335.9M | |
Other Liab | 19.6K | 16.5K | 127.4K | 20.4K | 18.3K | 17.4K | |
Net Tangible Assets | 49.0M | 79.2M | 194.0M | 167.1M | 192.2M | 201.8M | |
Other Assets | (55.2K) | 198.2M | (446.0K) | 115.4M | 132.7M | 139.3M | |
Net Receivables | 309.5K | 489.0K | 6.2K | 135.1K | 121.6K | 115.5K | |
Liabilities And Stockholders Equity | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
Inventory | 420.5K | (360.8K) | (309.5K) | 110.6M | 127.2M | 133.6M | |
Short Term Debt | 59.1K | 120.7K | 133.8K | 80.3K | 92.4K | 87.8K | |
Common Stock Shares Outstanding | 22.4M | 38.5M | 44.0M | 44.1M | 50.7M | 53.2M | |
Non Current Liabilities Total | 127K | 230.6K | 77K | (71.0) | (63.9) | (60.7) | |
Short Long Term Debt Total | 59.1K | 331.0K | 209.8K | 80.3K | 72.3K | 68.7K | |
Net Invested Capital | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 103.4M | |
Net Working Capital | 79.1M | 193.7M | 166.7M | 145.3M | 167.1M | 101.6M | |
Capital Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 198.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.